Sierra Biopharma is developing therapeutics that selectively neutralize, remove, and destroy immune components that lead to autoimmune diseases, starting with the orphan indication myasthenia gravis (MG). Sierra Biopharma has developed an antigen-specific therapeutic for MG that targets pathogenic antibodies (Abs) and the memory B-cells (mBCs) that lead to their production. This biologic compound currently binds to and neutralizes the main immunogenic region (MIR) in directed pathogenic Abs and should eliminate their mBCs.
Myasthenia Gravis (MG) causes weakness and rapid fatigue of muscles under voluntary control and is caused by an antibody-mediated autoimmune response. Current treatment options include acetylcholinesterase inhibitors (with modest efficacy at improving neurotransmission). The prevalence in the U.S. is estimated at 20 cases per 100,000 people. The vaccine utilizes cytoplasmic domains of human AChR subunits and incomplete Freund’s adjuvant.
LignaMed is a biotechnology company developing breakthrough treatments for asthma, organ transplant viability, and pulmonary fibrosis. Many of these conditions suffer from localized ischemia-reperfusion injury due to local hypoxia. LignaMed's lead candidate LGM2605 is a novel small molecule synthetic lignan with anti-inflammatory and antioxidant properties. LignaMed expects to file an Investigational New Drug application with the U.S. Food and Drug Administration (FDA) in 2021 for Airway Hyperreactivity (AHR) in Th2-low asthma, a subtype of glucocorticoid resistant asthma. LignaMed is recruiting a CEO to take its breakthrough pharmaceutical and device technologies from pre-clinical studies to clinical trials and FDA approval and/or exit with a strategic pharmaceutical or device company.
Volatile organic compounds (VOCs) are carbon containing molecules that have low boiling points and high vapor pressures causing them to evaporate into gas phase at ambient conditions. A wide range of VOC analysis devices are used in various industries for occupational exposure monitoring, environmental monitoring, process control, detection of explosive compounds, and medical diagnosis. Gas chromatography mass spectrometry (GCMS) is the gold standard method for analysis of VOCs. However, these systems are bulky, expensive, and sophisticated laboratory instruments that require skilled professionals for operation. ProTech’s VOCSense is a sensor-based analysis technology that resembles the functionality of a gas chromatography mass spectrometry system. VOCSense can identify and quantify individual VOCs from normal air samples. ProTech is looking for a C-level leader and advisors to support them during development and fundraising.
Multidrug-resistant Gram-negative bacilli (MDRGNB) have emerged as a challenging cause of hospital-acquired infections and present a critical need for innovative antibacterial development. Two new oxopyrazole agents targeting penicillin binding proteins (PBPs) based on a non-beta-lactam core have superior MIC50 values to current billion-dollar last resort antibiotics like Ceftazidime/Avibactam or Meropenem. One shows broad Gr- efficacy while the second oxopyrazole is selective for Acenitobacter baumannii. On target, good in vivo PK, no mammalian toxicity, no off-target liability. Seeking funding for definitive in vivo efficacy studies.
Gateway Bio is developing an innovative “PEG-like” drug conjugation technology that eliminates the antigenicity issues surrounding PEGylation today. Gateway Bio was specifically formed to translate several scientific breakthroughs from the lab of Professor Chilkoti at Duke University into commercially viable products and processes by combining the expertise of the academic scientists closest to these technologies with the business acumen of experienced start-up professionals. The initial core technology of Gateway Bio is based on several key patents on POEGMA conjugates that have been successfully licensed from Duke by Gateway Bio. Our novel method of creating PEG-like conjugates could be applied to generics, existing drugs, newly developed drugs or any of the PEGylated pharmaceuticals currently on the market. There are currently 15 FDA-approved peglyated drugs, with dozens more in clinical trials. Sales of the two most successful pegylated products, Pegasys and Neulasta, exceeded $5 billion in 2011.
Functional brain imaging is an important tool to assess brain health in conditions like stroke, cognitive function, visual function disorders, Parkinson’s, and ischemia. However, the MRI scanners are too bulky and expensive to bring the assessment where it is needed at the bedside or in ambulatory settings. EsperDyne's Wearable Optical Brain Imaging (WOBI) system addresses the cost and portability gap, bringing affordable functional brain imaging to the bedside and beyond. The market size for fNIRS Brain Imaging Systems is currently estimated at more than $135M with a CAGR of 10% as the systems gain additional research and clinical importance. The two known competing research systems lack the voxel density and portability of the WOBI system. The WOBI technology is protected by two issued and two pending US patents and has 3 prototype generations.
90% of cancer-related deaths occur due to metastasis. While effective therapies exist to treat primary tumors, treatments to slow/stop metastasis remain ineffective. While immuno-oncology is a new avenue for fighting these metastasized tumors, priming the immune cells has proven difficult. Here, the lab of Prof. King demonstrates a new method to functionalize immune cells. This technology can be applied to metastatic forms of prostate (1.1 million men diagnosed in 2012) and colorectal cancer (1.2 million cases diagnosed in 2015.)
Using patent-pending technology developed at Vanderbilt University, our technique overcomes cost and scaleability limitations associated with traditional manufacturing techniques, while also giving commercial viability to carbon conversion technologies through the introduction of a high-value secondary material produced from greenhouse gas inputs. Our technique relies on electrochemistry, rather than solely catalysis, and results in a highly efficient process to convert atmospheric carbon dioxide into useful functional nanomaterials.
Operating rooms are often not efficient and are costly to hospitals. Solutions to increasing efficiency neglect to monitor errors in real time which can be stopped and improve efficiency from the time of the incident. This technology pairs artificial intelligence with real time monitoring of operating room procedures to increase efficiency of hospital operating rooms.
MedGyde develops ligand and antibody directed products which bind to antigens specific to various cancer subtypes. MedGyde’s pipeline includes antibodies and single-chain variable fragments which have demonstrated cytotoxic properties. The products have therapeutic as well as diagnostic applications (theranostic). MedGyde has also developed a radio-sensitization technology that targets and sensitizes cancer cells. The lead therapeutic antibody to inducible neoantigen, TIP1, binds specifically to cancer. It has been conjugated to both radiopharmaceuticals and chemotherapy which markedly improved cancer cures in pre-clinical cancer models. The planned clinical trial will be in patients with advanced non-small cell lung cancer. MedGyde has been awarded several NIH small business grants to further develop antibodies and nanoparticle drug delivery systems. Venture capital is needed for GMP manufacturing and IND enabling safety testing.
Magnets form the core of a wide variety of power electronic devices including motors, inductors and transformers. New magnetic materials are needed to meet the high performance requirements for grid modernization (solid state transformers, PV inductors, sensors); for EVs and aviation (inductors, sensors, motors); and for industrial motor controls (inductors, sensors).
Working men and women lift every day. They do it in warehouses and on production lines. In offices and combat zones. Every day, they lift the economy worldwide. Whether it’s the day-to-day grind or responding to a crisis, their strength supports us all. And they deserve gear that sustains their strength, for work and for life. That makes their job safer. The HeroWear Apex means that their weight is over. The world’s first exosuit for all, built from the ground up for both men and women, the Apex is a back-assist exosuit that uses a proprietary band-based mechanism to reduce strain on the back without getting in the way.
Loss of brain synapses is highly correlated with symptom progression in Alzheimer’s dementia, but there is currently no treatment to slow or halt synapse loss. Allyx’s prion protein antagonists rescue synapses and memory function by interrupting the deleterious signaling triggered by amyloid without removing plaque itself and are effective at reversing deficits after they develop.
Long gap peripheral nerve injuries (i.e., gaps >3cm) remain a clinical challenge. When there is a long gap nerve injury, the standard of care is transplanting a nerve from one place in the body to the area where the defect is, a technique known as autografting. The use of an autograft requires a second surgical site resulting in longer operating times, and typically a sensory nerve is used to replace a motor/sensory nerve, which leaves an area of the body with permanent numbness. There are a handful of nerve guides on the market available to regenerate nerve gaps less than 1 inch. However, there are no synthetic guides available having an FDA-approved indication for use in nerve gaps greater than one inch. Our patented technology utilizes a biodegradable tube containing a controlled drug delivery system supplying the cues necessary to promote the growth of nerves over large gaps, thus fulfilling this clinical unmet need.
Each year millions of people suffer from symptoms of sore throat, laryngitis and cough due to colds and inflammation of the upper aerodigestive tract. Current methods of treatment are suboptimal and rely primarily on throat gargles, sprays, and lozenges, which treat only the mouth and part of the upper throat. They completely miss 50% of the inflamed area. This product is an OTC inhaled liquid mist that is inexpensive, portable, disposable, natural, tastes good, and is more effective because it treats the entire upper aerodigestive tract. The target market would be everyday people with cough, voice and sore throat complaints, as well as singers and voice professionals.
Oxidative stress is an imbalance between reactive oxygen species (ROS) and antioxidant defense mechanisms. Oxidative stress causes damage to proteins, lipids, DNA, cells, and tissues, which contributes to numerous age-related disorders including inflammation, cardiovascular diseases, neurodegeneration, and cancer. NADPH oxidase (NOX) enzymes produce ROS and are key targets for attenuating excessive oxidative species. ROS-NOX Pharma has developed NOX inhibitors, which selectively block activity of NOX isoforms 1 and 2. NOX inhibitors can be developed to treat oxidative stress disorders. ROS-NOX Pharma is seeking advisors, entrepreneurs, and introductions to VCs.
AnelleO is harnessing the advancements in the speed and scale of 3D printing technology for novel solutions in Women’s Health. AnelleO’s Intravaginal Rings (IVRs) offer a unique platform for sustained delivery of therapeutics – a non-invasive, self-administered and retrievable platform that can deliver drugs over a period of weeks or months. AnelleO is a medical device company that is developing a 3D printed intravaginal ring that can be used as a platform for treating a wide range of women's health conditions. Their first product, AnelleO PRO involves the only single administration of progesterone for infertility. Their technology enables controlled drug-release kinetics with up to 100% drug release, as well as rapid manufacturing and custom sizing. The manufacturing method allows for formulation of biologics and drug combinations not possible with traditional technologies.
We have applied a unique, robust, and comprehensive image-based assay developed in our laboratory to discover small molecule inhibitors of nucleolar function. Results from pilot screens on FDA-approved drugs reveal 83 unique hits that include known and putative antineoplastic agents.
Prof. Bob Datta and his team at Harvard Medical School have discovered a new class of odorant receptors - MS4As - that is structurally distinct from previously known receptors. In fact, data suggests that stimulating MS4A-bearing cells can significantly increase food intake in mice by hijacking innate preference mechanisms. The screening platform developed by Bob Datta has the potential to unlock numerous naturally-occurring ligands to create unique additives for food and/or fragrances. The science of the MS4As represents the first truly new opportunity to develop a new class of compounds with the potential to influence human and animal olfactory perception. Sandeep Robert (Bob) Datta is an Associate Professor of Neurobiology at Harvard and he is an entrepreneurial faculty member who is currently working on a number of start-ups.
VitalCore is a Medical Devices Integration (MDI) solution that provides an integrated platform for showing the status, error messages, and patient info stored across all devices in various hospitals. VitalCore provides a visualized form of status data for easier comprehension and viewership by using tables, bar graphs, line charts, pie charts, and donut charts that enable the users to grasp the trend of the data and generate insights efficiently to improve patient care and reduce costs. Compared to similar device connectivity monitoring providers, VitalCore is focused on medical devices and has an active pilot that provides both an HL7 viewer and mobile application for healthcare professionals on the go. VitalCore is looking to expand their leadership team as they prepare to fundraise.
In orthopaedic surgery, procedures commonly include fixation of bone and soft tissues. Currently, surgical manipulation of these bones and soft tissues is accomplished by the application of manual force either directly on tissue or through devices that transmit forces to the tissue including pins, screws, bolts, straps, and clamps. These methods of performing orthopaedic surgery have several disadvantages: Manual force is limited by the strength and endurance of the surgeon and surgical assistants, manual manipulation has limited precision, reliance on manual manipulation exposes the surgeon and surgical assistants to increased radiation exposure when intra-operative fluoroscopy is used to confirm position during manipulation of bone. ARTS is developing the Robotic Surgical Assist Arm (RSAA), a motorized rigid traction system which standardizes and facilitates the correct placement of the bones. Focusing on long bone repair the initial market would be in the area of 100,000 cases annually in America.
ClostraBio is a preclinical-stage pharmaceutical company creating new medicines to treat diseases resulting from intestinal barrier dysfunction, especially those caused by shifts to the microbiome. ClostraBio's first indications are in the treatment and prevention of food allergy, initially peanut allergy, and ClostraBio recently began a program in colitis. ClostraBio has licensed a proprietary drug delivery platform, developed by the ClostraBio co-founders, from the University of Chicago and are using this platform for oral delivery of small molecules and metabolites derived from the microbiome to the GI tract. ClostraBio's founding scientific team are key opinion leaders and world's experts in food allergy, the microbiome, immunology and immuno-engineering, drug delivery, and polymer chemistry. ClostraBio is seeking a Chief Executive Officer and Chief Medical Officer.
Modulation of MAP Kinase Phosphatases in Targeting Liver Disease. A novel platform for allosteric targeting of MAP kinase phosphatases to achieve nodal regulation of signaling pathways that can be leveraged for therapeutic purposes.
The scientific community is continuously trying to improve their understanding of genetic mechanisms in biological systems and finding biomarkers for diagnosis, prognosis and treatment. With growing accessibility, still, only the minority of investigators in the life and medical sciences has the means to analyze and leverage this enormous treasure of data. Bioada is an integrated, easy to use and interactive genomics data analysis platform for the broader community of life scientists.
Wounds outside and inside the body are common and can be devastating. Wound adhesives have not been able to compete with suturing due to lack of strength and flexibility. LiMAX has developed a gel adhesive using biomimicry which is able to outperform existing medical adhesives in strength and flexibility. LiMAX is focusing on the application to skin first, but the applications of the technology span many tissues.
Knee cartilage injuries in young active people have unique challenges that do not face older patients. The treatments need to be able to withstand intense activity and last for years. There is currently no gold standard treatment, with all solutions having significant drawbacks in price, recovery time, and/or longevity of treatment. Nanochon has developed a 3D printed synthetic cartilage replacement which is inserted with minimally invasive surgery and encourages new tissue growth, extending the lifetime of the treatment.
About half of treated cancer patients receive platinum-based drugs (eg. cisplatin, carboplatin) alone or in co-administration with other anticancer agents. Despite their efficacy, their use is limited by toxic side effects and inherent or acquired resistance to platinum-based drugs by tumor cells. To address this challenge, a Cornell team lead by Prof. Justin Wilson have developed rhenium-based chemotherapeutics for treatment of platinum-resistant cancers.
Wolfram Syndrome is an orphan disease that has no treatment. Wolfram Syndrome is caused by mutations in wolframin, a protein that is necessary for normal function in cells, by binding to and preventing cleavage of neuronal calcium sensor 1 (NCS1). Center Pharm's drug candidate targets the cleavage site of NCS1. The drug will stabilize NCS1 levels and maintain normal cell functions to delay disease progression.
Arrhythmia symptoms range from shortness of breath and fatigue to sudden cardiac arrest or stroke. The disease also greatly decreases the quality of life by limiting physical activity and inducing a significant psychological burden. Catheter ablation is a minimally-invasive procedure that is one of the most effective treatments for arrhythmia. Unfortunately, nearly half of patients who undergo a first multi-hour ablation therapy will find that the procedure did not successfully treat their arrhythmia, will often time lead to new arrhythmias, and will most likely need to be repeated at least once. Visiblate is a software-based imaging technology that monitors and maps lesion formation in real time during catheter ablation surgery, reducing the likelihood of subsequent ablation procedures and reducing costs.
Cancer patients, after the first diagnosis often ask, “how bad is my tumor and what should I do if it is bad?” In about half of all cancer patients, the first line of chemotherapy fails, disease recurs, and patients die. Episteme has succeeded in targeting a specific epigenetic signature of pancreatic cancer patients, which could potentially be reverted by epigenetic drugs making the tumors amenable to chemotherapy. Episteme invented a novel microarray-based platform technology called “ATAC-Array”. This proprietary technology avoids the time and cost of next-generation ATAC library sequencing – the only microarray that reads chromatin accessibility. No other test provides such a comprehensive, cost-effective and clinically useful epigenetic summary. Episteme offers a personalized theragnostic test utilizing ATAC-array, histopathology and immunohistochemistry, to predict chemotherapy response and stratifying cancer patients to epigenetic (reprograming) therapy for better outcome and better quality of life.
Exotanium is a startup created by two professors and one graduated Ph.D. student from the Department of Computer Science at Cornell University. Exotanium is developing a new cloud-native application container platform that improves performance, security, and cost for both public and private clouds. The technology is based on cutting-edge research and is patent-protected. Exotanium recently won a Small Business Innovation Research (SBIR) award from the National Science Foundation (NSF) and is actively raising more investments. The company is located in Ithaca, NY.
Existing brain perfusion systems are focused on preserving immediately harvested organs until transplantation. These systems are not applicable to research and development applications where the organs may not be immediately obtained postmortem. OrganEx has developed an effective method to salvage organs ex-vivo to advance clinical research and transplantation studies.
New biomarker for novel CD8 T cell subset that drives systemic sclerosis immunopathology, including monoclonal antibodies anti-human C10orf128 and new targets for small molecule inhibitor therapy. Monoclonal antibodies recognized 5-10% of circulating T cells. Humanized version of them are likely therapeutic agent for systemic sclerosis after humanization. Also so likely have a monoclonal antibody specific for mouse homolog of C10orf128 to enable an animal preclinical model for T cell depletion studies. There is no effective treatment for systemic sclerosis; 50,000 individuals have Ssc; fatal disease. Potential applications include pulmonary fibrosis, asthma with scarring among others.
Venohood is a custom cuff attachment to the venous end of an arteriovenous graft that reduces graft failure by lowering rate of thrombosis at the venous anastomosis. Venohood is founded by Prof. Mohamed Zayed, the co-founder and CMO of Caeli Vascular. Dr. Zayed is a rising star in fostering innovation at Washington University in St. Louis, with 8 new medtech inventions over the past 3 years. His disclosures have lead to four patent filings and one license to his startup, Caeli.
Cognivive develops FDA-registered, personalized, evidence-based, prescription digital therapeutics used by patients at home to treat neuromotor and neurocognitive impairments resulting from stroke.
The current standard for distinguishing between benign and cancerous skin legions require an invasive skin biopsy followed by a waiting period for lab results for diagnosis. OptoVibronix is eliminating the need for invasive skin biopses to diagnose a skin legion as cancerous or benign. The technology scans the skin legion and results in a diagnosis in just 15 minutes. By avoiding skin biospy, it improves the patient experience and efficiency of diagnosis and reduces healthcare costs.
The Synaural platform uses engineered acoustic probes to elicit specific neural activity within the brain. A robust, easy to use, non-invasive headset records the neural activity and patented algorithms extract unique metrics that provide objective insight to the subject’s neural health and can be used to guide treatment in a meaningful, measured way. To date, the metrics have demonstrated enough specificity to be correlated with various conditions e.g. concussion, learning disabilities (e.g. Autism, reading, dyslexia), and hearing.
Cancer drug efficacy is limited by dosage restructions based on side effects of cancer drugs on healthy cells. Targeting drugs to tumors specifically can substantially improve the efficacy of existing drugs, and reduce the unpleasant side effects of cancer treatment. Cytosolix is using the high acidity characteristic of tumors to preferentially target drugs to these cells. The platform is applicable to 95% of cancers and 90% of those therapies, giving Cytosolix the opportunity to revolutionize drug design in oncology.
With Gates Foundation funding, Dr. Larry Zwiebel at Vanderbilt University has created a powerful insect repellant technology that repels all insects. Testing, so far, indicates no adverse affects to people, animals or the environment. Vanderbilt is forming a company to commercialize the technology. The first field for which the company will develop a product is the facility perimeter treatment market in the US. This includes homes, buildings and other structures. The annual market for the perimeter treatment products (without service cost) is about $10 billion. The annual growth of the market is about 4%, and the demand growth is considerably higher for products that are "green".
This device allows for damage free handling of sensitive devices and surfaces, and for applications that involve quick attach and release of surfaces. The total market opportunity for this company is approximately 36 billion. Conventional techniques to grab surfaces use a vacuum/suction strategy but these suffer an intrinsic limit of adhesion strength—1 atm (approximately 100 kPa) and are bulky. The switchable adhesion device is an electro-osmotic pump that uses individually-controlled oscillating water droplets to easily, carefully and quickly pick and place tiles in parallel.
Rubitection is developing a skin health and wellness system to improve assessment and care management of dermatological, plastic surgery, and vascular conditions with an initial application to early bedsores detection. Bedsores are an $11 billion healthcare problem at affects 2.3 million each year killing 60K. If detected early they can be prevented, but low cost early detection tools are not available. Our Rubitect Assessment System (RAS) empowers any caregiver in hospitals, nursing homes, and in home care to detect bedsore early and support care management. Rubitection’s issued patents, and exclusive worldwide license provide barriers to competitors. The RAS’ low risk FDA pathway allows a quick path to a $4.1 billion US bedsore market. Two recurring revenues supports long term sustainability. Within 5 - 6 years of product launch, Rubitection will generate $48 million in sales using a hybrid sales model. Rubitection will exit through acquisition to a wound care company like Hill-Rom, or 3M.
Cayuga Biotech is a preclinical therapeutics company developing therapies for bleeding disorders. Our lead candidate is a platelet-like drug that accelerates clotting in the presence of injury. Cayuga has already held its pre-IND meeting with the FDA and received guidance on the GLP trials required for IND approval. The Cayuga team is made up of PhD scientists who developed CAY001 during their PhD research. We have two KOLs who are experts in the field of hemostasis and have overseen clinical trials on anticoagulant reversal drugs. Our regulatory strategy is developed by an advisor who spent 23 years at the FDA in CDER. Our manufacturing advisor has overseen 9 drugs reach clinical trials and 4 drugs receive approval. Our business advisors have overseen 4 successful business exits worth over $1 B. Cayuga has raised over $2 MM from DARPA and the Army. We are raising a round to complete the remaining IND-enabling studies, add experienced drug developers to the team, and prepare for the first in man trial.
We have developed a novel linker technology that can enable potent targeting of nanomedicines for therapeutic and diagnostic applications. We further have a unique clinical pipeline for development of this technology using ex vivo perfusion of non-transplanted human organs. Our primary lab, the Tietjen lab, has developed a robust pipeline for preclinical research on human kidney and liver with the capacity to expand to heart and lung in the future. This provides a direct path to clinical impact in organ transplantation and will enable broad translation for a variety of indications.
A Novel Platform to Develop piRNA-Based Therapeutics for Cancer Treatment. PIWI-interacting RNAs (piRNAs) is a novel pathway for nucleic acid based targeted therapy. piRNAs consist of small non-coding RNAs that interact with PIWI proteins. The PIWI/piRNA pathway protects the genome from destabilizing transposon activity by using piRNA to guide PIWI proteins to transposable genome sites, leading to gene specific methylation in somatic cells. piRNAs offer potential advantages because the longer piRNA seed sequences results in higher target specificity, higher tissue specificity, higher efficacy, and lower toxicity over siRNA and miRNA techniques. Short-term focus is currently on treating liver cancer because of the relative ease of drug delivery and lack of effective treatments.
While obesity is a growing worldwide epidemic, there are few effective treatments. This technology aims to inhibit a degradation pathway, therefore increasing heat and calorie burn in patients with obesity.
Parkinson's disease (PD) is characterized by uncontrolled tremors and issues with movement and balance. It affects 1-2% of people over 65, costing the US over $35 billion a year. Current treatments for PD, such as L-DOPA and deep brain stimulation (DBS), only treat the motor symptoms but are not able to fix the underlying cause of the deficits: loss of the nigrostriatal pathway. To address this gap in clinical care, the first “tissue engineered nigrostriatal pathway” was developed outside the body and precisely microinjected as a unit to “wire in” and physically replace the missing pathway, “reversing the clock” on the neurodegenerative progression of PD. Preliminary results in animal models show success recreating the pathway which delivers the dopamine signals that are lost in PD patients. Full pitch deck available upon request.
Currently available drug-eluting stents release drugs such as sirolimus or everolimus, which stop smooth muscle growth to prevent in-stent restenosis. However, they also block endothelial cell growth and create risk of thrombosis and mandate long-term antiplatelet medication. Nevertheless, yearly, 10% of these stents fail due to late thrombosis or stenosis. We discovered a drug combination (Fas ligand and nitric oxide) which inhibits smooth muscle growth more potently than sirolimus or everolimus but does not affect endothelial growth. This project will lead to the development of a next generation DES with a unique biologically selective effect on smooth muscle and endothelium.
In the future, the power grid will be a large-scale network of distributed energy resources (DERs), each introducing random and rapid fluctuations in power supply, demand, voltage and frequency. These DERs provide tremendous opportunity for sustainability, efficiency, and power reliability. However, a major issue is how intelligent devices and independent producers can achieve maximum and reliable efficiency for the power network. Singularity's hardware-agnostic algorithmic platform can provide the intelligent control for the smart grid of the future.
The FloraPulse system is a microchip tensiometer (microtensiometer) that is embedded into the tree woody tissue and directly measures the water status, known as water potential. Because the measurement is taken directly inside the water-carrying tissue, readings are very accurate and reliable. You receive daily midday stem water potential readings, along with science-backed irrigation recommendations. Since 2017, we raised $1.2M in non-dilutive SBIR research awards to develop microT, and successfully field tested the product in almond, grape and prune commercial orchards and vineyards. In 2019-2020, we received $50k in customer deposits and sold the first 60 subscriptions ($90k) to 15 customers in the US, Chile and Australia. Customer feedback has been very positive. We are looking to hire a seasoned CEO to help the company raise funds, build partnerships, and continue increasing product sales in the US and abroad.